A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia
Ws. Fenton et al., A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia, AM J PSYCHI, 158(12), 2001, pp. 2071-2074
objective: This study determined if augmentation of neuroleptics with 3 g/d
ay of ethyl eicosapentaenoic acid (EPA) improves symptoms and cognition in
patients with schizophrenia or schizoaffective disorder.
Method: Eighty-seven patients meeting criteria for schizophrenia or schizoa
ffective disorder who had residual symptoms despite neuroleptic treatment w
ere randomly assigned to receive either 3 g/day of ethyl EPA (N=43) or plac
ebo (N=44) in a 16-week, double-blind supplementation trial. Assessments we
re performed at baseline and at weeks 1, 2, 4, 8, 12, and 16; a cognitive b
attery was administered at baseline and at week 16.
Results: No differences were found between groups in positive or negative s
ymptoms, mood, cognition, or global impression ratings. Results were simila
r for the intention-to-treat (N=87) and completer (N=75) groups.
Conclusions: For schizophrenia patients treated with 3 g/day of ethyl EPA,
improvement in residual symptoms and cognitive impairment was no greater th
an for schizophrenia patients treated with placebo.